Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines
Background: COVID-19 vaccines induce a differentiated humoral and cellular response, and one of the comparable parameters of the vaccine response is the determination of IgG antibodies. Materials and Methods: Concentrations of IgG anti-SARS-CoV-2 antibodies were analyzed at three time points (at the...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/1/99 |
| _version_ | 1797489872585359360 |
|---|---|
| author | Joanna Szczepanek Monika Skorupa Agnieszka Goroncy Joanna Jarkiewicz-Tretyn Aleksandra Wypych Dorota Sandomierz Aleksander Jarkiewicz-Tretyn Joanna Dejewska Karolina Ciechanowska Krzysztof Pałgan Paweł Rajewski Andrzej Tretyn |
| author_facet | Joanna Szczepanek Monika Skorupa Agnieszka Goroncy Joanna Jarkiewicz-Tretyn Aleksandra Wypych Dorota Sandomierz Aleksander Jarkiewicz-Tretyn Joanna Dejewska Karolina Ciechanowska Krzysztof Pałgan Paweł Rajewski Andrzej Tretyn |
| author_sort | Joanna Szczepanek |
| collection | DOAJ |
| description | Background: COVID-19 vaccines induce a differentiated humoral and cellular response, and one of the comparable parameters of the vaccine response is the determination of IgG antibodies. Materials and Methods: Concentrations of IgG anti-SARS-CoV-2 antibodies were analyzed at three time points (at the beginning of May, at the end of June and at the end of September). Serum samples were obtained from 954 employees of the Nicolaus Copernicus University in Toruń (a total of three samples each were obtained from 511 vaccinated participants). IgG antibody concentrations were determined by enzyme immunoassay. The statistical analysis included comparisons between vaccines, between convalescents and COVID-19 non-patients, between individual measurements and included the gender, age and blood groups of participants. Results: There were significant differences in antibody levels between mRNA and vector vaccines. People vaccinated with mRNA-1273 achieved the highest levels of antibodies, regardless of the time since full vaccination. People vaccinated with ChAdOx1 nCoV-2019 produced several times lower antibody levels compared to the mRNA vaccines, while the antibody levels were more stable. In the case of each of the vaccines, the factor having the strongest impact on the level and stability of the IgG antibody titers was previous SARS-CoV-2 infection. There were no significant correlations with age, gender and blood type. Summary: mRNA vaccines induce a stronger humoral response of the immune system with the fastest loss of antibodies over time. |
| first_indexed | 2024-03-10T00:22:50Z |
| format | Article |
| id | doaj.art-7672b2e5e14e4ff7bb9fd19c2a556cd5 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T00:22:50Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-7672b2e5e14e4ff7bb9fd19c2a556cd52023-11-23T15:39:24ZengMDPI AGVaccines2076-393X2022-01-011019910.3390/vaccines10010099Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S VaccinesJoanna Szczepanek0Monika Skorupa1Agnieszka Goroncy2Joanna Jarkiewicz-Tretyn3Aleksandra Wypych4Dorota Sandomierz5Aleksander Jarkiewicz-Tretyn6Joanna Dejewska7Karolina Ciechanowska8Krzysztof Pałgan9Paweł Rajewski10Andrzej Tretyn11Centre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, 87-100 Torun, PolandCentre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, 87-100 Torun, PolandFaculty of Mathematics and Computer Science, Nicolaus Copernicus University, 87-100 Torun, PolandCancer Genetics Laboratory Ltd., 87-100 Torun, PolandCentre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, 87-100 Torun, PolandCancer Genetics Laboratory Ltd., 87-100 Torun, PolandCancer Genetics Laboratory Ltd., 87-100 Torun, PolandCancer Genetics Laboratory Ltd., 87-100 Torun, PolandCancer Genetics Laboratory Ltd., 87-100 Torun, PolandDepartment of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum, Nicolaus Copernicus University, 85-067 Bydgoszcz, PolandDepartment of Internal and Infectious Diseases, Provincial Infectious Disease Hospital, 85-067 Bydgoszcz, PolandFaculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, 87-100 Torun, PolandBackground: COVID-19 vaccines induce a differentiated humoral and cellular response, and one of the comparable parameters of the vaccine response is the determination of IgG antibodies. Materials and Methods: Concentrations of IgG anti-SARS-CoV-2 antibodies were analyzed at three time points (at the beginning of May, at the end of June and at the end of September). Serum samples were obtained from 954 employees of the Nicolaus Copernicus University in Toruń (a total of three samples each were obtained from 511 vaccinated participants). IgG antibody concentrations were determined by enzyme immunoassay. The statistical analysis included comparisons between vaccines, between convalescents and COVID-19 non-patients, between individual measurements and included the gender, age and blood groups of participants. Results: There were significant differences in antibody levels between mRNA and vector vaccines. People vaccinated with mRNA-1273 achieved the highest levels of antibodies, regardless of the time since full vaccination. People vaccinated with ChAdOx1 nCoV-2019 produced several times lower antibody levels compared to the mRNA vaccines, while the antibody levels were more stable. In the case of each of the vaccines, the factor having the strongest impact on the level and stability of the IgG antibody titers was previous SARS-CoV-2 infection. There were no significant correlations with age, gender and blood type. Summary: mRNA vaccines induce a stronger humoral response of the immune system with the fastest loss of antibodies over time.https://www.mdpi.com/2076-393X/10/1/99SARS-CoV-2COVID-19Pfizer/BioNTechOxford/AstraZenecaModernaJanssen/Johnson & Johnson |
| spellingShingle | Joanna Szczepanek Monika Skorupa Agnieszka Goroncy Joanna Jarkiewicz-Tretyn Aleksandra Wypych Dorota Sandomierz Aleksander Jarkiewicz-Tretyn Joanna Dejewska Karolina Ciechanowska Krzysztof Pałgan Paweł Rajewski Andrzej Tretyn Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines Vaccines SARS-CoV-2 COVID-19 Pfizer/BioNTech Oxford/AstraZeneca Moderna Janssen/Johnson & Johnson |
| title | Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines |
| title_full | Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines |
| title_fullStr | Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines |
| title_full_unstemmed | Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines |
| title_short | Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines |
| title_sort | anti sars cov 2 igg against the s protein a comparison of bnt162b2 mrna 1273 chadox1 ncov 2019 and ad26 cov2 s vaccines |
| topic | SARS-CoV-2 COVID-19 Pfizer/BioNTech Oxford/AstraZeneca Moderna Janssen/Johnson & Johnson |
| url | https://www.mdpi.com/2076-393X/10/1/99 |
| work_keys_str_mv | AT joannaszczepanek antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT monikaskorupa antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT agnieszkagoroncy antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT joannajarkiewicztretyn antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT aleksandrawypych antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT dorotasandomierz antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT aleksanderjarkiewicztretyn antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT joannadejewska antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT karolinaciechanowska antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT krzysztofpałgan antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT pawełrajewski antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines AT andrzejtretyn antisarscov2iggagainstthesproteinacomparisonofbnt162b2mrna1273chadox1ncov2019andad26cov2svaccines |